Immunovant, Inc.
IMVT
$31.33
-$0.28-0.89%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.27M | 15.44M | 17.51M | 26.02M | 20.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 159.55M | 114.36M | 131.76M | 127.22M | 113.83M |
| Operating Income | -159.55M | -114.36M | -131.76M | -127.22M | -113.83M |
| Income Before Tax | -150.70M | -109.08M | -125.91M | -119.70M | -105.87M |
| Income Tax Expenses | -2.84M | 1.55M | 594.00K | 913.00K | 583.00K |
| Earnings from Continuing Operations | -147.86M | -110.64M | -126.50M | -120.61M | -106.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -147.86M | -110.64M | -126.50M | -120.61M | -106.45M |
| EBIT | -159.55M | -114.36M | -131.76M | -127.22M | -113.83M |
| EBITDA | -159.46M | -114.26M | -131.66M | -127.12M | -113.72M |
| EPS Basic | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 |
| Normalized Basic EPS | -0.46 | -0.38 | -0.45 | -0.44 | -0.40 |
| EPS Diluted | -0.73 | -0.61 | -0.73 | -0.71 | -0.64 |
| Normalized Diluted EPS | -0.46 | -0.38 | -0.45 | -0.44 | -0.40 |
| Average Basic Shares Outstanding | 203.71M | 181.51M | 173.64M | 170.87M | 166.73M |
| Average Diluted Shares Outstanding | 203.71M | 181.51M | 173.64M | 170.87M | 166.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |